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Defective IFN production and exacerbated inflammatory and pro-fibrotic responses are
hallmarks of SARS-CoV-2 infection in severe COVID-19. Based on these hallmarks, and
considering the pivotal role of macrophages in COVID-19 pathogenesis, we hypothesize
that the transcription factors MAFB andMAF critically contribute to COVID-19 progression
by shaping the response of macrophages to SARS-CoV-2. Our proposal stems from the
recent identification of pathogenic lung macrophage subsets in severe COVID-19, and
takes into consideration the previously reported ability of MAFB to dampen IFN type I
production, as well as the critical role of MAFB and MAF in the acquisition and
maintenance of the transcriptional signature of M-CSF–conditioned human
macrophages. Solid evidences are presented that link overexpression of MAFB and
silencing of MAF expression with clinical and biological features of severe COVID-19. As a
whole, we propose that a high MAFB/MAF expression ratio in lung macrophages could
serve as an accurate diagnostic tool for COVID-19 progression. Indeed, reversing the
macrophage MAFB/MAF expression ratio might impair the exacerbated inflammatory and
profibrotic responses, and restore the defective IFN type I production, thus becoming a
potential strategy to limit severity of COVID-19.
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of
Coronavirus Disease 2019 (COVID-19), has so far caused more than 1,000,000 deaths globally
(data from the WHO), and its huge clinical and social impact continues to be rising in spite of
unprecedented worldwide measures to limit its transmission and pathogenicity. Following the
COVID-19 outbreak, a large amount of epidemiological, clinical, and immunological information
has been increasingly gathered, as a complete understanding of COVID-19 pathogenesis should
allow the design of effective measures to boost the generation of effective anti-SARS-CoV-2 immune
responses. More than 80% of symptomatic COVID-19 patients present fever, cough and dyspnea
(mild cases), while 14% develop acute respiratory distress syndrome (ARDS) and systemic
inflammation (severe cases), and 5% show fibrosis at several organs, including lungs, and
coagulopathies, all of which lead to multiorgan failure (critical COVID-19 patients) (1). An
imbalanced host response to SARS-CoV-2 drives the development of COVID-19, as SARS-CoV-2org November 2020 | Volume 11 | Article 6035071
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but concomitantly promotes an exacerbated production of
cytokines (“cytokine storm”) and profibrotic factors, and
enhanced recruitment and accumulation of leukocytes in tissues
causing ARDS (2, 3). From an immunological perspective, severe
COVID-19 patients display a robust immune dysregulation,
including T cell and NK cell cytopenia, sustained cytokine
production and hyper-inflammation (4). These two later
manifestations closely resemble the macrophage activation
syndrome (5), a dysregulated macrophage response induced by
infections that results in a severe damage to the host tissues. It is
currently accepted that macrophages lie in the center of the
COVID-19 pathogenesis, and that, upon SARS-CoV-2 infection,
the excessive activation of pulmonary macrophages, besides
contributing to viral control, causes lung injury through the
inflammatory “cytokine storm” that spreads from the lung
throughout the body via the systemic circulation in COVID-19
patients (6, 7). Therefore, understanding the response of
monocytes and macrophages to SARS-CoV-2 infection (to the
virus itself, and to the systemic alterations triggered upon SARS-
CoV-2 interaction with other cell types) is essential to identify
potential therapeutic targets for COVID-19.MAFB AND MAF TRANSCRIPTION
FACTORS IN MACROPHAGES
MAFB andMAF belong to the large-MAF subfamily of transcription
factors that includes MAF, MAFA, MAFB, and NRL, which drive
terminal differentiation in numerous cell lineages (8). Although
MAFB and MAF display redundant roles in differentiation
processes [e.g., epidermal differentiation (9)], they can also exert
opposite functions, as in the case of cortical interneuron
development (10). Within the hematopoietic lineage, MAFB is
preferentially expressed in most tissue-resident macrophages,
whose specific enhancers contain an overrepresentation of MAF-
responsive element (MARE) sequences (11), and where it promotes
macrophage differentiation (12), and inhibits stemness and self-
renewal of differentiated monocytes and macrophages in
cooperation with MAF (13–15). Regarding macrophage cell
biology, both MAFB and MAF favor the maintenance of an “M2-
like” homeostatic and reparative phenotype inmacrophages (16, 17).
Thus, MAFB and MAF determine the anti-inflammatory and
immunosuppressive polarization of M-CSF–dependent human
macrophages (16) and Tumor-Associated Macrophages (TAMs)
(18, 19). Indeed, silencing of MAF expression in macrophages
leads to macrophage re-programming toward an M1-like
phenotype and enhancement of antitumor activities (19, 20). In
addition, MAFB has the ability of negatively regulating the
expression of type I IFN upon viral infection by setting a
threshold for IRF3-dependent transcription (21, 22). Specifically,
MAFB antagonizes antiviral responses as it blocks the recruitment of
coactivators to the transcription factor IRF3 (22), and suppresses the
monocyte production of type I IFN in chronic hepatitis C patients
(21). This function as “rheostat” for type I IFN (23) suggests thatFrontiers in Immunology | www.frontiersin.org 2MAFB might contribute to the defective IFN production in
COVID-19.MAFB/MAF IN COVID-19
The role of MAFB andMAF in shaping macrophage phenotype and
polarization prompted us to identify the genes regulated by these
transcription factors. To this end, we analyzed the transcriptional
profiles of M-CSF–conditioned human monocyte-derived
macrophages (as a model of homeostatic tissue-resident
macrophages) after siRNA-mediated knockdown of either MAFB
(siMAFB) or MAF (siMAF) (GEO accession number: GSE155719),
what led to the identification of more than 1000 genes whose
expression is MAFB- and/or MAF-dependent (adjp < 0.05; |Fold
change| > 1.5, GSE155719) (Simoń-Fuentes et al., manuscript in
preparation). Extensive gene ontology analysis of the MAFB/MAF-
dependent genes provided initial clues on the relevance of both
factors in shaping the transcriptome of homeostatic/tissue-resident
macrophages. First, Gene Set Enrichment Analysis (GSEA) on the
Hallmark gene sets collection (24) revealed that the genes positively
regulated by MAFB but inhibited by MAF are significantly enriched
in terms like “HALLMARK_INTERFERON_ALPHA_RESPONSE”,
“HALLMARK_INTERFERON_GAMMA_RESPONSE”, and
“HALLMARK_INFLAMMATORY_RESPONSE” (Figure 1),
which are strongly associated to the innate immune response
against SARS-CoV-2 infection. This enrichment is in agreement
with the involvement of MAFB andMAF in type I IFN expression
(22) and the establishment of a ‘‘negative IFN-gamma signature’’
in inflammatory macrophages, respectively (17). Noteworthy,
comparison of the GSEA leading edges for the “HALLMARK_
INFLAMMATORY_RESPONSE” and “HALLMARK_
INTERFERON_ALPHA_RESPONSE” gene sets with both
factors only showed a partial overlap, implying that MAFB and
MAF might affect both functions through regulation of common
and specific genes (Simo ́n-Fuentes et al., manuscript in
preparation). Regarding the “HALLMARK_INFLAMMATORY_
RESPONSE” gene set, MAFB and MAF were found to oppositely
regulate the expression of a cluster of chemokine-encoding genes
(CXCL10, CCL2, CCL7, CXCL9) that are associated to the
COVID-19 “cytokine storm” (25). A similar result was obtained
upon analysis of the GO Biological Pathways gene sets sub-
collection, which pointed to the involvement of the genes
regulated by both factors in leukocyte migration, another
COVID-19 trait (Figure 1). Next, analysis of the genes
differentially regulated by MAFB and MAF on the disease-
associated database DisGeNet using the clusterProfiler tool (26)
revealed a very significant enrichment of several terms related to
respiratory deterioration (a firmly established symptom of
COVID-19) (Figure 1). In fact, Enrichr analysis (27) on the
COVID-19 gene sets supported the association between MAFB-
and MAF-dependent genes and COVID-19 (Figure 1). Further,
analysis of theWikipathways database by clusterProfiler revealed a
significant association to the term COVID-19-AOP (adverse
outcome pathway). Specifically, MAF knock-down was found
associated to IL7, CCL2, IL1B, CXCL8, TNF, and CCL3 (q value,November 2020 | Volume 11 | Article 603507
Vega et al. MAF and MAFB in Severe COVID-192.82 × 10−4) while MAFB was associated to CCL2, IL2RA, IL10
and CXCL10 expression (q value, 6.73 × 10−3). Altogether, these
analyses strongly suggest a link between MAF/MAFB-regulated
genes and COVID-19 pathology.MAF AND MAFB SHAPE THE
TRANSCRIPTIONAL PROFILE OF TLR7-
ACTIVATED HUMAN MACROPHAGES
TLR7 is a sensor for SARS-Cov-2, and its relevance in COVID-19
is highlighted by the discovery of the association of loss-of-function
variants of X-chromosomal TLR7 with impaired type I and II IFN
responses and with severe COVID-19 (28). Thus, we next assessed
the expression of MAFB/MAF and their regulated genes in human
M-CSF–derived macrophages exposed to the TLR7 synthetic
ligand CL264 (GEO accession number: GSE156921) (Simoń-
Fuentes et al., manuscript in preparation). The expression of
MAFB and MAF in macrophages followed different kinetics
along TLR7 activation, with a huge decrease in MAF expression
and a continuously increasing MAFB/MAF expression ratio
(Figure 2A). If this trend is maintained at longer times, the
high-MAFB/low-MAF scenario would favor/promote COVID-19
pathology, as we have suggested above. Importantly, GSEA on theFrontiers in Immunology | www.frontiersin.org 3transcriptome of TLR7-activated macrophages (12 h) revealed a
significantly positive enrichment of genes inhibited by MAF, and a
concomitant negative enrichment of MAFB-regulated genes
(Figure 2B), again supporting an opposite role for MAFB and
MAF in determining the macrophage response to TLR7 activation,




To gather additional support for the hypothetic role of MAFB
and MAF in COVID-19 pathogenesis, we integrated our gene
expression data for MAFB and MAF within a “COVID-19
disease framework” built from data derived from single cell
transcriptomic experiments on macrophage populations
isolated from the lungs of both healthy and COVID-19
patients (29). Three main macrophage populations have been
identified in the interstitial space and bronchoalveolar lavage
fluid (BALF) from normal lungs samples (30), namely, FCN1high,
SPP1high and FABP4high. Analysis of bronchoalveolar lavage fluid
(BALF) from COVID-19 patients has revealed a markedlyFIGURE 1 | Summary of gene ontology evidences for the involvement of MAF and MAFB in COVID-19 progression and pathology-associated clinical parameters.
Ontology terms significantly associated to genes downregulated by MAFB-specific siRNA (positively regulated by MAFB, siMAFB DOWN) or upregulated by MAF-
specific siRNA (negatively regulated by MAF, siMAF UP), with indication of the analyzed databases. Normalized statistical significance of each association (−log10 p) is
shown, and derived from FDRq values (for GSEA), q values (clusterProfiler) and adjusted p (Enrichr).November 2020 | Volume 11 | Article 603507
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subsets in lungs from severe COVID-19 patients, what correlates
with disease progression, while the proportion of the resident-like
Alveolar Macrophages (AM) FABP4high subset is diminished (29)
(Figure 3A, left panel). The FCN1high subset is derived from
circulating monocytes, while the origin of the SPP1high
(MERTKhigh) subset is so far unclear (pulmonary or monocyte-
derived) (30–32). Whereas the FCN1high subset displays a pro-
inflammatory phenotype (29), the SPP1high subset is increased in
pulmonary fibrosis (30), is located in fibrotic areas (30, 31), and its
gene signature and co-localization with fibroblast foci strongly
suggests their identity as the key profibrotic macrophage in human
pulmonary fibrosis (32–35). Importantly, self-maintenance and
persistence of the SPP1high subset is dependent on M-CSF/M-
CSFR signaling (35), what correlates with their specific expression
of MAFB (33, 34), the high number of MAFB+ CD68+
macrophages detected in pulmonary fibrosis patients (33, 34)
and their expression of MAFB-dependent pro-fibrotic genes like
LGMN (16, 36, 37). Finally, the FABP4high subset represents the
GM-CSF–dependent resident alveolar macrophages, which are
essential for the maintenance of lung homeostasis.
To assess the pathological significance of our hypothesis, the
expressionof the genesmost differentially expressedby theFCN1high,
SPP1high, and FABP4high subsets (29) was determined in humanM-
CSF–conditionedmacrophages after knockdown of eitherMAFB or
MAF. For MAFB, GSEA revealed that the transcriptome of the pro-Frontiers in Immunology | www.frontiersin.org 4fibrotic SPP1high subset is positively enriched in MAFB-dependent
genes [groups2and3 in (29),Figure3B, rightpanel], includinggenes
coding for chemokines that are integral part of the “cytokine storm”
(CCL2,CCL3,CCL4,CCL7,CXCL9,CXCL10,CXCL11). Conversely,
MAFB downregulation resulted in enhanced expression of the genes
that characterize the transcriptome of FABP4high alveolar
macrophages [AM, group 4 in (29)]. Thus, MAFB appears to shape
the transcriptome of the pathogenic pro-fibrotic SPP1high
macrophage subset, whose levels are increased in severe COVID-19
(16, 29). Thisfinding is also in agreementwith theMAFB-dependent
expression of numerous genes involved in fibrosis, including LGMN,
THBS1, FBLN5, GAS6, SERPINB2, PRLR, and FBN2 [(16)
and GSE155719].
In the case of MAF, GSEA revealed that the gene signature of
the FCN1high subset [designated as groups 1 and 2 in (29)], is
enriched in MAF-inhibited genes, as the Groups of genes
preferentially expressed by the FCN1high subset (Group 1 and
2) include a significant over-representation of genes upregulated
upon MAF knock-down (Figure 3B, right panel). Of note, the
specific transcriptome of the FCN1high subset includes genes
coding for chemokines (e.g., CCL2, CCL3, and CXCL10) and pro-
inflammatory factors, in agreement with its “classic M1-like
macrophage” phenotype (29) (Figure 3B, right panel).
Conversely, and unlike MAFB, MAF expression appeared to
have an opposite effect on the expression of genes specifically
associated to the FABP4high subset [group 4 in (29)]. Therefore,A
B
FIGURE 2 | Expression of MAF, MAFB and MAF/MAFB-dependent genes along TLR7 activation of M-CSF–dependent human macrophages. (A) (Left panel)
Expression of MAF and MAFB in M-CSF–dependent human monocyte-derived macrophages exposed to the TLR ligand CL264 (100 ng/ml) (GSE156921). (Right
panel) Evolution of the MAFB/MAF expression ratio along TLR7 activation of M-CSF–dependent human monocyte-derived macrophages. (B) GSEA of the gene sets
containing genes inhibited by MAF (siMAF UP, left panel) or upregulated by MAFB (siMAFB DOWN, right panel) on the ranked comparison of the transcriptome of
TLR7-activated M-CSF–dependent human monocyte-derived macrophages (12 h, TLR7-activated M-MØ) versus the transcriptome of untreated macrophages (M-
MØ). Normalized Enrichment Score (NES) and FDRq values are indicated.November 2020 | Volume 11 | Article 603507
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inflammatory macrophage activation, and suggest that
deprivation of MAF expression also contributes to shaping the
transcriptional profile of pro-inflammatory lung macrophages
with a pathogenic role in COVID-19. Moreover, analysis of the
leading edge genes in their respective GSEA contours showed
that MAFB and MAF oppositely regulate the expression of
chemokines that contribute to the SARS-CoV-2–induced “cytokine
storm” (CCL2, CCL4, CCL7, CCL8, CXCL10, CXCL11), some of
which have been already proposed as useful biomarkers for COVID-
19 severity and progression (38). Consequently, we hypothesize that
MAFB and MAF shape the transcriptome of the fibrotic SPP1high
and inflammatory monocyte-derived FCN1high pulmonary
macrophage subsets, respectively, which exert a pathogenic role in
severe COVID-19. If so, the expression of genes oppositely regulated
by MAFB and MAF might constitute helpful biomarkers for
COVID-19 severity, as already demonstrated in the case of
CXCL10 (38), and imply that the MAFB/MAF expression ratio in
lung macrophages is a critical determinant for COVID-19 severity
and progression.
Further supporting our hypothesis, additional GSEA also
revealed co-enrichment of genes positively regulated by MAFB
and negatively regulated by MAF in bronchoalveolar lavage fluid
cells in COVID-19 patients (39) (data not shown). In fact, aFrontiers in Immunology | www.frontiersin.org 5similar result was observed in other pathological and experimental
settings, including synovial membranes from Rheumatoid Arthritis
patients [GSE1919 (40)], as well as LPS-activated Alveolar
Macrophages [GSE40885 (41)] and IFNa-activated monocyte-
derived macrophages [GSE16755 (42)] (data not shown). More
importantly, analysis of the DisGeNET (https://www.disgenet.org)
and Disease Ontology (DO, https://disease-ontology.org) databases
of gene-disease associations also disclosed that the genes positively
regulated by MAFB and negatively regulated by MAF are
significantly associated to infectious/inflammatory diseases (e.g.,
pneumonia, glomerulonephritis, juvenile arthritis, rheumatoid
arthritis, multiple sclerosis,…) (data not shown). Taken together,
these data provide an additional support for the occurrence of an
altered effective MAFB/MAF ratio in severe COVID-19 and chronic
inflammatory disorders.
To deepen into the potential molecular mechanisms underlying
the control of gene expression by a high MAFB/MAF expression
ratio in macrophages, we searched for transcription factors
differentially modulated upon knock-down of MAFB or MAF in
M-CSF–derived macrophages (GSE155719). This analysis revealed
that the Aryl hydrocarbon Receptor (AhR) is positively regulated by
MAFBwhile negatively regulated byMAF. AhR is a ligand-activated
transcription factor that regulates inflammatory responses, shapes
adaptive immunity and controls the differentiation potential ofA B
FIGURE 3 | Expression of MAF- and MAFB-dependent genes in human lung macrophage subsets associated to pulmonary fibrosis and COVID-19 severity.
(A) Previously identified human lung macrophage subsets (29–32), with indication of their relative levels in healthy individuals and moderate COVID-19 patients (left)
and severe COVID-19 patients (right), as well as representative genes specifically expressed by each macrophage subset. (B) GSEA of the gene sets that define the
human lung macrophage subsets (Group1 for the FCN1+ subset, Group 2 for the FCN1+ and SPP1+ subsets, Group 3 for the SPP1+ subset, Group 4 for the
FABP4+ subset) on the ranked comparison of the transcriptomes of MAFB-specific siRNA-transfected (siRNA MAFB M-MØ) (left panels) or MAF-specific siRNA-
transfected (siRNA MAF M-MØ) (right panels) versus the transcriptome of control siRNA-transfected macrophages (siRNA control M-MØ). Normalized Enrichment
Score (NES) and FDRq values of each analysis are indicated.November 2020 | Volume 11 | Article 603507
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affect the expression of AHR, and an enhanced MAFB/MAF ratio
correlates with an increased expression of AHR, as it is also seen in
macrophages activated by TLR4 or TLR7 ligands (our
transcriptional information in GSE156921). The MAFB/MAF
ratio-AHR expression link is of special relevance because AhR is
activated during coronavirus infection and the constitutive AhR
activation constrains type I IFN-mediated antiviral innate defense
(44, 45). In fact, a role for AhR in SARS-CoV-2 pathology has been
recently proposed (46), and AhR antagonists have been
propositioned as potential therapy for coronavirus-infected
patients (46). Therefore, considering the link between MAFB/
MAF ratio and AHR expression, the proposed involvement of
AhR in COVID-19 pathogenesis is well in agreement with our
hypothesis on the contribution of MAFB and MAF to severe
COVID-19.DISCUSSION
The altered MAFB/MAF expression ratio that we have found
might have prognostic value in COVID-19 severity and
progression, as well as potential therapeutic implications. On the
prognosis issue, an immediate consequence of our hypothesis
would be that the genes positively regulated by MAFB or
negatively regulated by MAF could be prognostic biomarkers for
severe COVID-19. In this regard, recent reports seem to support
the validity of our hypothesis and its prognostic significance. In
fact, some of the genes whose expression is oppositely regulated by
MAF and MAFB have been already described as biomarkers for
COVID-19 severity, including CXCL10 (38) and, more recently,
CCL19 (47). Moreover, SARS-CoV-2 infected individuals have a
consistent chemokine signature that appears to be a driving feature
of COVID-19 infection and includes monocyte-associated
chemokines like CCL2 and CCL8 (48), whose expression is also
differentially regulated by MAF and MAFB (Simoń-Fuentes et al.,
manuscript in preparation).
Regarding the potential therapeutic value of altering the MAFB/
MAF ratio, it is worth noting that both factors are similarly regulated
byGSK3b (8), and that the effect of theMAF inhibitorNivalenol (19)
on MAFB is currently unknown. Therefore, and considering their
different capacity to heterodimerize with several AP-1 superfamily
factors (8), it is tempting to postulate that the heterodimeric partners
of MAFB and MAF might represent points of intervention to
modulate the effective MAFB/MAF ratio. Initial experiments on
this issue indicate that JNK inhibition preferentially impairs the
expression of MAF and MAF-regulated genes without affecting
the expression of MAFB-dependent genes (Simoń-Fuentes et al.,
manuscript in preparation), illustrating the feasibility of modulating
the effective MAFB/MAF ratio in human macrophages through
JNK inhibition. Thus, although MAPK inhibitors would affect
numerous intracellular signaling pathways and cellular functions,
this result poses the question of whether available modulators of
JNK andMAPK, already used in numerous clinical trials (49) might
be useful alternatives for reversing the outcome of the prevailing
MAFB/MAF ratio in lung macrophages in COVID-19.Frontiers in Immunology | www.frontiersin.org 6On the other hand, the possibility of altering the MAFB/MAF
ratio as a potential therapy for severe COVID-19 raises the
question of the appropriate timing for such an approach. The
issue of the more adequate time for therapeutic modulation of
the inflammatory response in COVID-19 is a matter of debate
and is very dependent on the course of the disease. As an
example, strategies aim at targeting the GM-CSF/GM-CSF
receptor axis have been proposed for distinct stages of the
disease (50). In the case of MAFB/MAF, and in spite of the
fact that both factors regulate the expression of monocyte-
recruiting chemokines and that monocytes give rise to the
pathogenic pulmonary macrophages in COVID-19, we
envision that altering the MAFB/MAF ratio should only be
tried during the overwhelming pro-inflammatory response at
the later stages of the disease, a time at which the consequences of
altering myeloid differentiation would be less detrimental.
The link between the MAFB/MAF ratio and the gene profile of
pathogenic macrophages in severe COVID-19 has also mechanistic
implications. In this respect, it is reasonable to assume that the
influence of MAF and MAFB on SARS-CoV-2–induced
inflammation and fibrosis not only reflects their specific
transcriptional activities, but also their capacity to heterodimerize
with members of the “large MAF” family as well as members of the
AP-1 superfamily of transcription factors (8). In this regard, MAFB
can dimerize with JUN, FOS and FRA1/2, while MAF dimerization
partners include FOS and ATF4 (8). Notably, AP-1 superfamily
factors are major effectors of MAPKs, whose activity modulates the
macrophage inflammatory program elicited by PAMP receptors
(51, 52) and is connected to the occurrence of the “cytokine storm”
during viral responses (53–55). Therefore, it is conceivable that
alterations in the MAFB/MAF ratio in macrophages may indirectly
dysregulate the modulatory action ofMAPKs on pro-inflammatory
cytokine/chemokine expression by shifting the transcriptional
functions of AP-1 factors. If that is the case, the currently
available MAPK-modifying drugs might represent potential
therapeutic alternatives for severe COVID-19.
In conclusion, and based on currently available transcriptional
information, we hypothesize that MAFB and MAF transcription
factors are key players in the pathogenic response of lung
macrophages to SARS-CoV-2 infection. In the case of MAFB, its
function as a “rheostat” for type I IFN production, and its ability to
shape the transcriptomeofpro-fibrotic SPP1high lungmacrophages,
suggest its participation in the defective type I IFN production and
the pro-fibrotic response that characterize severe COVID-19.
Regarding MAF, its ability to limit the expression of pro-
inflammatory cytokines and chemokines, and its negative effect
on the acquisition of the transcriptome of FCN1high pulmonary
macrophages, suggests its involvement in triggering the pro-
inflammatory “cytokine storm”, a major trademark of COVID-
19. The association of the expression of MAFB with the expression
of a significant number of monocyte-recruiting chemokines
induces us to propose that MAFB also contributes, although
possibly with a lower extent than MAF, to the “cytokine storm”.
Thus, we propose that the expression levels of MAFB and MAF in
FCN1high and SPP1high pulmonary macrophage subsets are critical
determinants for the defective production of IFN type I, theNovember 2020 | Volume 11 | Article 603507
Vega et al. MAF and MAFB in Severe COVID-19overwhelming hyper-inflammatory response, and the exacerbated
profibrotic response that takes place upon severe SARS-CoV-2
infection (Figure 4). By extension,MAFB/MAF expression ratio in
lungmacrophages appears to be a critical determinant for COVID-
19 severity and progression and, therefore, therapies directed to
simultaneously silencing MAFB and overexpressing MAF in
pulmonary macrophages might constitute suitable strategies to
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analyzed data. ÁD-S, MV, and AC designed the research and
analyzed data. MV and AC wrote the paper. All authors
contributed to the article and approved the submitted version.FUNDING
This work was supported by grants from Consejo Superior de
Investigaciónes Cientı ́ficas (202020E228), Ministerio de
Economıá y Competitividad (SAF2017-83785-R), and AYUDAS
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